Kymab - Ownership and Business Overview

Life ScienceCompany

Kymab Ownership

Who owns Kymab?

Kymab is owned by Sanofi SA. It was acquired on January 11, 2021.

Kymab Business Overview

Where is Kymab headquartered?

Kymab is headquartered in Cambridge, United Kingdom.

What sector is Kymab in?

Kymab is a life science company.

When was Kymab founded?

Kymab was founded in 2010.

Life Science M&A Summary in 2021

Out of 60 sectors in the Mergr database, life science ranked 7 in number of deals in 2021. The largest life science acquisition in 2021 was Pharmaceutical Product Development - which was acquired by Thermo Fisher Scientific for $17.4B.

Join Mergr to view all 388 acquisitions of life science companies in 2021, including 44 acquisitions by private equity firms, and 344 by strategics.

Kymab

The Bennet Building (B930), Babraham Research Campus,
Cambridge, CB22 3AT
United Kingdom,
+44 (0)1223 833301
www.kymab.com

Kymab is a clinical-stage biopharmaceutical company developing fully human monoclonal antibody therapeutics with a focus on immune-mediated diseases and immuno-oncology using its proprietary, integrated platforms collectively called IntelliSelect®. Kymab’s IntelliSelect Transgenic platforms contain a full diversity of human antibodies, making them the most comprehensive antibody platforms available. Kymab was founded in 2010 and is based in Cambridge, United Kingdom.


 Subscribe to unlock this and 202,225
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 194K M&A Transactions
  • 198K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 75K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.